Grail (NASDAQ:GRAL) Reaches New 12-Month High – Should You Buy?

Grail, Inc. (NASDAQ:GRAL) shares hit a new 52-week high on Wednesday . The company traded as high as $63.99 and last traded at $47.23, with a volume of 5368896 shares trading hands. The stock had previously closed at $55.02.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GRAL. Wolfe Research began coverage on shares of Grail in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Morgan Stanley assumed coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price for the company.

Grail Stock Performance

The business’s 50-day moving average price is $24.61 and its 200-day moving average price is $18.40.

Institutional Investors Weigh In On Grail

A number of hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC bought a new stake in shares of Grail during the 4th quarter valued at $26,000. State of Tennessee Department of Treasury bought a new position in Grail in the 4th quarter worth $28,000. Lindbrook Capital LLC bought a new position in Grail in the 4th quarter worth $28,000. Sterling Capital Management LLC bought a new position in Grail in the 4th quarter worth $29,000. Finally, Wellington Shields Capital Management LLC bought a new position in Grail in the 4th quarter worth $33,000.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.